How is CJC-1295 classified in scientific research?
CJC-1295 is engineered for prolonged GHRH activity, while Ipamorelin is studied as a selective ghrelin receptor agonist. They are investigated together in laboratory research because they act through different receptor pathways.
Mechanism Studied in Research
Published studies have investigated:
GHRH Receptor — CJC-1295 signaling.
Ghrelin Receptor — Ipamorelin activity.
GH and IGF-1 Axis — Experimental biomarker research.
These findings describe published scientific research only and should not be interpreted as evidence of clinical safety, effectiveness, or approved therapeutic use.
Research background
CJC-1295 and Ipamorelin have been investigated separately in published laboratory research. Combination products remain investigational reference materials.
Purity, testing and handling
Researchers should verify CJC-1295 + Ipamorelin using lot-specific COAs and batch documentation before laboratory use.